Pharmaengine Inc., of Taipei, Taiwan, said the Committee for Medicinal Products for Human Use of the EMA has adopted a positive opinion recommending the granting of a marketing authorization of Onivyde (irinotecan liposome injection, nal-IRI) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) to treat metastatic adenocarcinoma of the pancreas in adult patients who have progressed following gemcitabine based therapy.